Teva Pharmaceutical Industries LimitedTEVANYSE
LOADING
|||
Year-over-year net income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 53.55% |
| Q2 2025 | 31.78% |
| Q1 2025 | 198.62% |
| Q4 2024 | 50.34% |
| Q3 2024 | 48.35% |
| Q2 2024 | -508.63% |
| Q1 2024 | -130.02% |
| Q4 2023 | 571.01% |
| Q3 2023 | 107.91% |
| Q2 2023 | -296.36% |
| Q1 2023 | 81.98% |
| Q4 2022 | -2280.36% |
| Q3 2022 | 124.14% |
| Q2 2022 | 75.71% |
| Q1 2022 | -500.63% |
| Q4 2021 | -154.45% |
| Q3 2021 | 41.06% |
| Q2 2021 | 168.83% |
| Q1 2021 | -48.67% |
| Q4 2020 | 103.45% |
| Q3 2020 | -3206.43% |
| Q2 2020 | 102.90% |
| Q1 2020 | -36.70% |
| Q4 2019 | 134.71% |
| Q3 2019 | 54.43% |
| Q2 2019 | -556.19% |
| Q1 2019 | 96.36% |
| Q4 2018 | -1287.50% |
| Q3 2018 | -18.18% |
| Q2 2018 | -116.68% |
| Q1 2018 | 109.15% |
| Q4 2017 | -2276.42% |
| Q3 2017 | 108.88% |
| Q2 2017 | -1129.31% |
| Q1 2017 | 159.61% |
| Q4 2016 | -379.60% |
| Q3 2016 | 37.01% |
| Q2 2016 | -55.44% |
| Q1 2016 | 14.00% |
| Q4 2015 | 385.44% |